Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMARIN CORP PLC\UKAMRN · Entity 5970 | Director | April 18, 2026 | April 21, 2026 |
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | March 09, 2026 | March 12, 2026 |
| Innoviva, Inc.INVA · Entity 4679 | Director | June 17, 2024 | June 20, 2024 |
| Sarissa Capital Acquisition Corp.SRSA · Entity 145567 | Senior Managing Director | October 20, 2020 | October 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMARIN CORP PLC\UK
Report date April 18, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 836 |
Last balance in matching sequence
After 2026-04-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-04-18 · Exercise / conversion · Acquired 838 · Balance 1,239 F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted 2,514 RSUs under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027. F3: Not applicable. Row 2 · 2026-04-18 · Tax withholding · Disposed 403 · Balance 836 F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 838 |
Reported balance
After 2026-04-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-18 · Exercise / conversion · Acquired 838 · Balance 838 F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion. F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted 2,514 RSUs under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027. F3: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.
F2: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted 2,514 RSUs under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027.
F3: Not applicable.
F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.
Armata Pharmaceuticals, Inc.
Report date March 09, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2036-03-09 | Direct | 25,640 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 25,640 · Balance 25,640 F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Innoviva, Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,625 |
Reported balance
After 2024-06-17 transaction · row 1
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 13,923 · Balance 122,625 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
| Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $16.16 · Expires 2034-06-16 | Direct | 30,000 |
Reported balance
After 2024-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-17 · Grant · Acquired 10,000 · Balance 30,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Sarissa Capital Acquisition Corp.
Report date October 20, 2020 · Filed October 20, 2020
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 18, 2026 Filed Apr 21, 2026 21:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Unit · Derivative | 838 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-167119 · ownership.xml · derivative · entry 3 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838 Underlying: American Depositary Shares · 838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion. F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2 · derivative.exercise_date: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted 2,514 RSUs under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027. F3 · derivative.expiration_date: Not applicable. F1 · derivative.underlying: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · derivative.underlying_shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| April 18, 2026 Filed Apr 21, 2026 21:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingAmerican Depositary Shares | 403 | $14.98 | $6,036.94 |
DisclosureSEC source: 0001193125-26-167119 · ownership.xml · nonDerivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 836 F1 · security: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| April 18, 2026 Filed Apr 21, 2026 21:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionAmerican Depositary Shares | 838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-167119 · ownership.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2 · kind: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted 2,514 RSUs under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027. F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F3 · price: Not applicable. F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| March 09, 2026 Filed Mar 12, 2026 01:15 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 25,640 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001104659-26-026583 · tm268588-6_4seq1.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,640 Underlying: Common Stock · 25,640 shares Expires 2036-03-09 F1 · derivative.exercise_date: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. Read SEC document |
| April 18, 2025 Filed Apr 23, 2025 01:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionRestricted Stock Unit · Derivative | 838 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-056929 · ownership.xml · derivative · entry 3 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,676 Underlying: American Depositary Shares · 838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion. F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2 · derivative.exercise_date: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award that vests in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027 F3 · derivative.expiration_date: Not applicable F1 · derivative.underlying: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · derivative.underlying_shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| April 18, 2025 Filed Apr 23, 2025 01:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Tax withholdingAmerican Depositary Shares | 437 | $9.11 | $3,981.07 |
DisclosureSEC source: 0000950170-25-056929 · ownership.xml · nonDerivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 401 F1 · security: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F4 · kind: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities. F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| April 18, 2025 Filed Apr 23, 2025 01:00 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | Exercise / conversionAmerican Depositary Shares | 838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-056929 · ownership.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F2 · kind: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award that vests in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027 F1 · shares: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. F3 · price: Not applicable F1 · balance_after: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:22 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-25-010568 · tm255864-9_4seq1.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,343 Underlying: Common Stock · 54,343 shares Expires 2035-02-05 F1 · derivative.exercise_date: The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:57 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001104659-24-073447 · tm2417570-3_4seq1.xml · derivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:57 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 13,923 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073447 · tm2417570-3_4seq1.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,625 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 20:35 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Unit · Derivative | 50,287 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-046054 · ownership.xml · derivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,287 Underlying: Ordinary Shares · 50,287 shares Expires not disclosed F3 · security: Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F4 · derivative.exercise_date: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an award of 50,287 RSUs under the Plan and the Policy. These RSUs vest in three equal installments on each of April 18, 2025, April 18, 2026 and April 18, 2027. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 18, 2024 Filed Apr 19, 2024 20:35 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (right to buy) · Derivative | 179,795 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0000950170-24-046054 · ownership.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,795 Underlying: Ordinary Shares · 179,795 shares Expires 2034-04-18 F1 · derivative.exercise_date: On April 18, 2024, following the conclusion of the Issuer's annual general meeting of shareholders for 2024, the Reporting Person was granted an option to purchase 179,795 Ordinary Shares under the Plan and the Policy. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the remaining balance vesting in equal quarterly installments over the subsequent two years on the first day of each April, July, October and January. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:00 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035724 · tm249071-5_4seq1.xml · derivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,009 Underlying: Common Stock · 54,343 shares Expires 2034-03-14 F2 · derivative.exercise_date: The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:00 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 39,666 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035724 · tm249071-5_4seq1.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,666 Underlying: Common Stock · 39,666 shares Expires 2034-03-14 F1 · derivative.exercise_date: The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024. Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 02:53 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 10,461 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001104659-23-129364 · tm2333426-1_4seq1.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 Underlying: Common Stock · 10,461 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock option vests immediately prior to the Company's 2024 annual shareholders meeting. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:16 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 60,268 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-033912 · ownership.xml · derivative · entry 4 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,268 Underlying: Ordinary Shares · 60,268 shares Expires not disclosed F4 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F7 · derivative.exercise_date: On July 21, 2023, following the conclusion of the Issuer's annual general meeting of shareholders for 2023, the Reporting Person was granted an award of 60,268 RSUs under the Plan and the Policy. These RSUs vest in full upon the earlier of the one-year anniversary of the grant date and the annual general meeting of shareholders in such anniversary year. The RSUs are subject to deferred settlement upon the director's separation of service with the Issuer. F6 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:16 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantRestricted Stock Units · Derivative | 94,866 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-033912 · ownership.xml · derivative · entry 3 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,866 Underlying: Ordinary Shares · 94,866 shares Expires not disclosed F4 · security: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. F5 · derivative.exercise_date: In connection with the Reporting Person's initial appointment to the Issuer's board of directors, on July 21, 2023 the Reporting Person was granted a one-time grant of 94,866 RSUs under the Plan and the Policy. These RSUs vest in equal annual installments over three years from the date of the Reporting Person's initial appointment to the Issuer's board of directors. The RSUs are subject to deferred settlement upon the director's separation of service with the Issuer. F6 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:16 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 180,804 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000950170-23-033912 · ownership.xml · derivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,804 Underlying: Ordinary Shares · 180,804 shares Expires 2033-07-21 F3 · derivative.exercise_date: On July 21, 2023, following the conclusion of the Issuer's annual general meeting of shareholders for 2023, the Reporting Person was granted an option to purchase 180,804 Ordinary Shares under the Plan and the Policy. This option shall vest and become exercisable upon the earlier of the one-year anniversary of the grant date and the annual general meeting of shareholders in such anniversary year. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| July 21, 2023 Filed Jul 22, 2023 01:16 UTC | AMARIN CORP PLC\UK AMRN · Entity 5970 | GrantStock Option (Right to Buy) · Derivative | 258,598 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0000950170-23-033912 · ownership.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,598 Underlying: Ordinary Shares · 284,598 shares Expires 2033-07-21 F1 · derivative.exercise_date: In connection with the Reporting Person's initial appointment to the Issuer's board of directors, on July 21, 2023 the Reporting Person was granted a one-time option to purchase 284,598 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan") and the Non-Employee Director Compensation Policy, as revised in May 2023 (the "Policy"). This option shall vest and become exercisable in equal annual installments over three years from the date of the Reporting Person's initial appointment to the Issuer's board of directors. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:47 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001104659-23-064209 · tm2316873-1_4seq1.xml · derivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-21 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| May 22, 2023 Filed May 24, 2023 21:47 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064209 · tm2316873-1_4seq1.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,702 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:47 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 10,000 | $10,000.00 Strike: $17.79 | $100,000,000.00 |
DisclosureSEC source: 0001567619-22-009041 · doc1.xml · derivative · entry 2 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2032-04-24 Read SEC document |
| April 25, 2022 Filed Apr 27, 2022 22:47 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-009041 · doc1.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,207 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 19:52 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001104659-22-046449 · tm2212851-5_4seq1.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-04-13 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:25 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001104659-21-078785 · tm2119245-1_4seq1.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| May 14, 2021 Filed May 21, 2021 00:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 17,482 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010829 · doc1.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,560 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") upon the conclusion of the Issuer's 2021 annual meeting of stockholders. 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 21:05 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001104659-20-133628 · tm2038059-2_4seq1.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 20:38 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-008547 · doc1.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,078 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:39 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 27,383 | $0.00 Strike: $4.17 | $0.00 |
DisclosureSEC source: 0001104659-20-022126 · tm208184-4_form4.xml · derivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 Underlying: Common Stock · 27,383 shares Expires 2030-02-12 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document |
| April 24, 2019 Filed May 25, 2019 01:58 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 16,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-031862 · a4.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,161 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 20:55 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 14,249 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005892 · edgar.xml · nonDerivative · entry 1 Odysseas Kostas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,762 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 23:23 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 14,513 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015803 · edgar.xml · nonDerivative · entry 1 Kostas Odysseas D · CIK 0001483080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,513 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.